May-Levin F - Search Results

1

Pamidronate infusions as single-agent therapy for bone metastases: a phase II trial in patients with breast cancer.

Tyrrell CT, Bruning PF, May-Levin F, Rose C, Mauriac L, Soukop M, Ford JM. Tyrrell CT, et al. Among authors: may levin f. Eur J Cancer. 1995 Nov;31A(12):1976-80. doi: 10.1016/0959-8049(95)00469-6. Eur J Cancer. 1995. PMID: 8562151 Clinical Trial.

2

Is the negative prognostic value of high oestrogen receptor (ER) levels in postmenopausal breast cancer patients due to a modified ER gene product?

Sancho-Garnier H, Delarue JC, Mouriesse H, Contesso G, May-Levin F, Gotteland M, May E. Sancho-Garnier H, et al. Among authors: may levin f. Eur J Cancer. 1995 Oct;31A(11):1851-5. doi: 10.1016/0959-8049(95)00387-x. Eur J Cancer. 1995. PMID: 8541112

3

Phase II study of mitozolomide (M & B 39,565) in colorectal and breast cancer.

Herait P, Rougier P, Oliveira J, Delgado FM, May-Levin F, Hayat M, Armand JP. Herait P, et al. Invest New Drugs. 1988 Dec;6(4):323-5. doi: 10.1007/BF00173652. Invest New Drugs. 1988. PMID: 3229944

4

Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer.

Toussaint C, Izzo J, Spielmann M, Merle S, May-Levin F, Armand JP, Lacombe D, Tursz T, Sunderland M, Chabot GG, et al. Toussaint C, et al. Among authors: may levin f. J Clin Oncol. 1994 Oct;12(10):2102-12. doi: 10.1200/JCO.1994.12.10.2102. J Clin Oncol. 1994. PMID: 7931480 Clinical Trial.

5

Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer.

Spielmann M, Dorval T, Turpin F, Antoine E, Jouve M, Maylevin F, Lacombe D, Rouesse J, Pouillart P, Tursz T, et al. Spielmann M, et al. J Clin Oncol. 1994 Sep;12(9):1764-70. doi: 10.1200/JCO.1994.12.9.1764. J Clin Oncol. 1994. PMID: 8083698 Clinical Trial.

6

Phase II study of elliptinium in advanced breast cancer.

Rouësse JG, Le Chevalier T, Caille P, Mondesir JM, Sancho-Garnier H, May-Levin F, Spielmann M, De Jager R, Amiel JL. Rouësse JG, et al. Cancer Treat Rep. 1985 Jun;69(6):707-8. Cancer Treat Rep. 1985. PMID: 4016774

7

Surgical and chemotherapeutic treatment of hepatic metastases from carcinoma of the breast.

Elias D, Lasser P, Spielmann M, May-Levin F, el Malt O, Thomas H, Mouriesse H. Elias D, et al. Among authors: may levin f. Surg Gynecol Obstet. 1991 Jun;172(6):461-4. Surg Gynecol Obstet. 1991. PMID: 2035135

8

Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression.

May E, Mouriesse H, May-Levin F, Qian JF, May P, Delarue JC. May E, et al. Br J Cancer. 1990 Sep;62(3):430-5. doi: 10.1038/bjc.1990.312. Br J Cancer. 1990. PMID: 1976381 Free PMC article.

9

A new approach allowing an early prognosis in breast cancer: the ratio of estrogen receptor (ER) ligand binding activity to the ER-specific mRNA level.

May E, Mouriesse H, May-Levin F, Contesso G, Delarue JC. May E, et al. Oncogene. 1989 Aug;4(8):1037-42. Oncogene. 1989. PMID: 2761986

10

Combined overexpression of c-erbB-2 protein and epidermal growth factor receptor (EGF-R) could be predictive of early and long-term outcome in human breast cancer: a pilot study.

Delarue JC, Terrier P, Terrier-Lacombe MJ, Mouriesse H, Gotteland M, May-Levin F. Delarue JC, et al. Among authors: may levin f. Bull Cancer. 1994 Dec;81(12):1067-77. Bull Cancer. 1994. PMID: 7742595

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

51 results

Search Page

Filters